Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.

Frontiers in endocrinology - 1 Jan 2022

Bolger Graeme B

Abstract excerpt

The cAMP-signaling cancers, which are defined by functionally-significant somatic mutations in one or more elements of the cAMP signaling pathway, have an unexpectedly wide range of cell origins, clinical manifestations, and potential therapeutic options. Mutations in at least 9 cAMP signaling pathway genes (TSHR, GPR101, GNAS, PDE8B, PDE11A, PRKARA1, PRKACA, PRKACB, and CREB) have been identified as driver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Neoplasms
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Phosphodiesterase function and regulation

Share to Receptor Mechanisms and Signaling

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 36313756
DOI: 10.3389/fendo.2022.1024423
PMCID: PMC9612118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.PMID 36313756Read ↗

Gαs-Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling.Semantic proximity Read ↗

cAMP/PKA signaling defects in tumors: Genetics and tissue-specific pluripotential cell-derived lesions in human and mouseSemantic proximity Read ↗

Phosphodiesterases and cAMP Pathway in Pituitary DiseasesSemantic proximity Read ↗

G Protein-Coupled Receptors in CancerSemantic proximity Read ↗

PRKAR1A and Thyroid TumorsSemantic proximity Read ↗

Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapySemantic proximity Read ↗

Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspectsSemantic proximity Read ↗

PKA drives paracrine crisis and WNT4-dependent testis tumor in Carney complexSemantic proximity Read ↗

Carney Complex: Pathology and Molecular GeneticsSemantic proximity Read ↗

Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigmSemantic proximity Read ↗

Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/− or Rb1+/− backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signalingSemantic proximity Read ↗

cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.